MetaCap

Corvus Pharmaceuticals (CRVS) vs Mentari Therapeutics (MTRI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Mentari Therapeutics is the larger company by market cap ($856.9 million vs $815.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRVS-35.14%MTRI+0.68%
+40%-0%-41%
Aug 17, 20261 yearNov 20, 2026
CRVS-33.13%MTRI+0.68%
+30%-3%-37%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRVS versus MTRI key metrics
MetricCRVSMTRI
Share price$9.67$14.70
Market cap$815.69M$856.94M
1-day change-3.40%-3.57%
YTD return+25.58%—
1-year return+12.84%—
5-year return+183.58%—
EPS (TTM)$-0.72—
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-15.28M—
52-week high$26.95$23.30
52-week low$6.39$5.75
Distance from 52-week high-64.12%-36.91%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+225.75%—
Average volume1.05M19.42K
Shares outstanding84.35M58.30M
Employees37—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Corvus Pharmaceuticals

CRVS stock →

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees

About Mentari Therapeutics

MTRI stock →

Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways.

Health Care · Biotechnology: Pharmaceutical Preparations

CRVS vs MTRI FAQ

Which is bigger, Corvus Pharmaceuticals or Mentari Therapeutics?

Mentari Therapeutics (MTRI) is larger, with a market capitalization of $856.94M compared with $815.69M for Corvus Pharmaceuticals (CRVS).

Are Corvus Pharmaceuticals and Mentari Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons